Fig 2. Progression-free survival (PFS) and overall survival (OS) according to antacid use among patients with epidermal growth factor receptor-mutant non-small-cell lung cancer who were treated using first-line tyrosine kinase inhibitors.

(top) PFS among patients who were receiving proton pump inhibitors, histamine H2-receptor antagonists, or no antacid. (bottom) OS among patients who were receiving proton pump inhibitors, histamine H2-receptor antagonists, or no antacid.